Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | £26 | £22 | £36 | £45 |
| - Cash | £1 | £1 | £1 | £1 |
| + Debt | £6 | £11 | £12 | £8 |
| Enterprise Value | £31 | £31 | £47 | £52 |
| Revenue | £44 | £39 | £35 | £29 |
| % Growth | 13.1% | 13.3% | 17.5% | – |
| Gross Profit | £20 | £17 | £16 | £14 |
| % Margin | 44.2% | 43.6% | 45.6% | 47.2% |
| EBITDA | £11 | £9 | £8 | £7 |
| % Margin | 24% | 23.9% | 23.8% | 25% |
| Net Income | £6 | £5 | £5 | £5 |
| % Margin | 13.1% | 11.8% | 14.8% | 17.4% |
| EPS Diluted | 13.07 | 10.34 | 11.48 | 11.49 |
| % Growth | 26.4% | -9.9% | -0.1% | – |
| Operating Cash Flow | £8 | £6 | £5 | £6 |
| Capital Expenditures | -£2 | -£3 | -£3 | -£3 |
| Free Cash Flow | £6 | £3 | £3 | £3 |